Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FSPG PET for IBD Activity
NCT03546868Phase 2Completed
- Sponsor
- The Asan Foundation
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Florilglutamic acid F-18 in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (2 arms), sponsored by The Asan Foundation. Primary endpoints: Sensitivity and specificity of active disease and Sensitivity and specificity of severe disease (presence of ulceration). Started Aug 2018; status: completed.
02
Drugs
Florilglutamic acid F-18
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03546868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546868.